Q1 2024 · 13F-HR
5AM Venture Management, LLCholdings as filed
Filed 2024-05-15 · accession 0001104659-24-061973
$446.6M
Reported value
26
Positions
2024-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $67.5M | 15.1% | 3,835,975 | Common | SOLE |
| 29384C108 | TRDA | ENTRADA THERAPEUTICS INC | $62.5M | 14.0% | 4,408,379 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $37.3M | 8.34% | 1,242,029 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $24.7M | 5.53% | 548,825 | Common | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC NEW | $20.9M | 4.67% | 497,270 | Common | SOLE |
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $20.7M | 4.65% | 340,000 | Common | SOLE |
| 92686J106 | VKTX | VIKING THERAPEUTICS INC | $19.5M | 4.36% | 237,560 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $18.4M | 4.13% | 797,600 | Common | SOLE |
| G1110E107 | BHVN | BIOHAVEN LTD | $17.5M | 3.92% | 319,972 | Common | SOLE |
| 05370A108 | RNAGBP | AVIDITY BIOSCIENCES INC | $17.0M | 3.80% | 665,555 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $15.4M | 3.45% | 939,298 | Common | SOLE |
| 929033108 | — | VOR BIOPHARMA INC | $15.1M | 3.38% | 6,361,723 | Common | SOLE |
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $14.2M | 3.18% | 282,313 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $14.1M | 3.15% | 1,245,000 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $12.9M | 2.89% | 736,595 | Common | SOLE |
| 82686Q101 | SLN | SILENCE THERAPEUTICS PLC | $10.3M | 2.30% | 476,200 | Common | SOLE |
| 032724106 | ANAB | ANAPTYSBIO INC | $8.1M | 1.80% | 357,733 | Common | SOLE |
| 98943L107 | ZNTL | ZENTALIS PHARMACEUTICALS INC | $7.7M | 1.73% | 490,000 | Common | SOLE |
| 00773U207 | AVU0 | ADVERUM BIOTECHNOLOGIES INC | $7.7M | 1.71% | 541,666 | Common | SOLE |
| 75120L100 | — | RALLYBIO CORP | $6.7M | 1.50% | 3,630,724 | Common | SOLE |
| G3855L106 | GHRS | GH RESEARCH PLC | $6.1M | 1.37% | 572,665 | Common | SOLE |
| 810648105 | SCPH | SCPHARMACEUTICALS INC | $6.0M | 1.35% | 1,200,647 | Common | SOLE |
| 59045L106 | — | MERSANA THERAPEUTICS INC | $5.8M | 1.31% | 1,305,000 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $5.3M | 1.19% | 790,440 | Common | SOLE |
| 746964105 | QTTB | Q32 BIO INC | $4.3M | 0.96% | 251,994 | Common | SOLE |
| 171757107 | — | CIDARA THERAPEUTICS INC | $1.0M | 0.23% | 1,134,511 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.